Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
Sainz de la Maza S, Sabin Muñoz J, Pilo de la Fuente B, Thuissard I, Andreu-Vázquez C, Galán Sánchez-Seco V, Salgado-Cámara P, Costa-Frossard L, Monreal E, Ayuso-Peralta L, García-Vasco L, García-Domínguez JM, Martínez-Ginés ML, Muñoz Fernández C, Díaz-Díaz J, Oreja-Guevara C, Gómez-Moreno M, Martín H, Rubio-Flores L, Blasco MR, Villar-Guimerans LM, Aladro Y; Dimethyl Fumarate Study Group.
Sainz de la Maza S, et al.
Mult Scler Relat Disord. 2022 Mar;59:103669. doi: 10.1016/j.msard.2022.103669. Epub 2022 Feb 4.
Mult Scler Relat Disord. 2022.
PMID: 35150979